Song Dong

Song Dong


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2025 in Medicine
Verified
Journal Article
Open access
HLHongzhou Liu
Hongzhou Liu
LXLang Xie
Lang Xie
YSYi Shen
Yi Shen
YDYangfan Du
Yangfan Du
JLJia Liu
Jia Liu
SDSong Dong
Song Dong
Thyroid cancer, particularly prevalent among women of childbearing age (WCBA), presents a growing global public health concern. This study examines the global, regional, and national burden of WCBA thyroid cancer from 1990 to 2021, with an emphasis on socioeconomic factors, including high body mass index. Data were drawn from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. We analyzed incidence, prevalence, disability-adjusted life years, and mortality rates for WCBA thyroid cancer, focusing on age-standardized rates. Temporal trends were quantified using the average annual percentage change. Inequalities were assessed using the concentration index; locally estimated scatterplot smoothing modeled age-standardized rate–sociodemographic index (SDI) relationships; decomposition identified contributions of population growth, aging, and epidemiologic change. From 1990 to 2021, the global incidence of WCBA thyroid cancer increased with an average annual percent change (AAPC) of 1.4% (95% confidence interval [CI]: 1.32–1.48), while prevalence rose at an AAPC of 1.44% (95% CI: 1.37–1.52). Conversely, the age-standardized mortality rate declined annually by 0.28% (95% CI: −0.4 to −0.16), and disability-adjusted life years showed no significant change (AAPC = −0.01, 95% CI: −0.18 to 0.17). The highest increase in disease burden was observed in low and low-middle SDI regions, with mortality rates linked to high body mass index rising by 2.19% annually. In contrast, high-SDI regions experienced a decrease in burden, with annual reductions in mortality rates ranging from 1.13% to 0.34%. Rising WCBA thyroid cancer incidence and prevalence, particularly in low SDI regions, highlight the urgent need for targeted prevention and health management strategies.

19 September 2025 in Medicine
Verified
Journal Article
Open access
YSYi Shen
Yi Shen
川宋川 宋
川 宋
YDYangfan Du
Yangfan Du
LWLinlin Wang
Linlin Wang
XLXiaojing Li
Xiaojing Li
HLHongzhou Liu
Hongzhou Liu
Klinefelter syndrome (KS) and Turner syndrome (TS) are among the most common congenital birth defects, with significant differences in both geographic distribution and temporal trends. There is a lack of updated data in China. This study aims to investigate the current situation and trend of the burden of KS and TS 1990 to 2021 in China and to make predictions for the future. This study is a descriptive and epidemiological analysis of the data from the 2021 global burden of diseases, injuries, and risk factors study. The incidence, prevalence, and disability-adjusted life-years (DALYs) of KS and TS in China are assessed by year and age. The estimated annual percentage changes were used to estimate the average changes in age-standardized rates (ASRs). Joinpoint regression analysis was used to assess the trend of KS and TS disease burden from 1990 to 2021. The Nordpred age-period cohort model was used to predict the DALYs, prevalence ASRs, and KS and TS cases from 2022 to 2042. From 1990 to 2021, KS incidence in China decreased by 54%, while TS incidence also showed a decline. However, DALYs and prevalence rates for both syndromes showed variable trends, with KS DALYs increasing and TS DALYs showing significant changes across different age groups. Projections indicate a decline in the number of DALYs and prevalence for both KS and TS from 2022 to 2042, despite an increase in ASRs. The study highlights significant age-related differences in the burden of Chinese KS and TS, with a decreasing trend in KS incidence and an increasing trend in TS-related complications. These findings underscore the need for improved understanding, early detection, and targeted interventions to mitigate the future burden of these diseases.

5 August 2026 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
HLHongzhou Liu
Hongzhou Liu
RWRu Wang
Ru Wang
HZHuadan Zhu
Huadan Zhu
CSChuan Song
Chuan Song
LSLi Shi
Li Shi
SYShuangtong Yan
Shuangtong Yan
Background: Although the triglyceride–glucose (TyG) index is an established surrogate marker of insulin resistance and metabolic burden, its relationship with hyperhomocysteinemia (HHcy) within the cardiovascular–kidney–metabolic (CKM) framework remains insufficiently understood. This study aimed to investigate the association between TyG and HHcy and to prioritize CKM-related biomarkers using interpretable machine learning and epidemiological modeling. Methods: This retrospective cross-sectional study included 31,116 adults undergoing health examinations. HHcy was defined as serum homocysteine >15 μmol/L. The relationships among CKM-related biomarkers were characterized using smooth curve fitting, Spearman correlation heatmaps, and network visualization. An extreme gradient boosting model coupled with SHapley Additive exPlanations was used to evaluate feature importance for HHcy identification. Sequential multivariable logistic regression and restricted cubic spline analyses were performed to assess the linear and nonlinear associations between TyG and HHcy. Subgroup and sensitivity analyses were conducted to assess the robustness of the observed associations, including alternative adiposity adjustment, creatinine-based estimated glomerular filtration rate substitution, and restriction of extreme TyG values. Results: Network analysis showed that TyG clustered predominantly with adiposity and metabolic indices, whereas homocysteine showed closer connectivity with renal-function-related markers. Within the prespecified CKM-related candidate feature set, creatinine ranked highest for HHcy identification, whereas TyG provided limited incremental discriminatory information beyond basic clinical characteristics. In sequential logistic regression, the TyG–HHcy association changed substantially across adjustment models: a crude positive association was attenuated and became inverse after adjustment for CKM-related covariates. In Model 4, which additionally adjusted for log(C-reactive protein + 1) and serum creatinine, each one-unit increase in TyG was associated with lower odds of HHcy (OR = 0.819, 95% CI: 0.765–0.877). Restricted cubic spline analysis indicated a significant nonlinear association (P-nonlinear < 0.001). Conclusion: TyG appears to be embedded as a metabolic component within a broader CKM biomarker network, whereas renal-function-related markers, particularly creatinine, are more closely linked to the HHcy phenotype. These findings support a CKM network-based interpretation of the TyG–HHcy relationship and highlight the relevance of metabolic–renal interrelationships in cardiometabolic risk assessment.

12 June 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
HLHongzhou Liu
Hongzhou Liu
RWRu Wang
Ru Wang
LCLiqin Cui
Liqin Cui
LWLinlin Wang
Linlin Wang
JLJia Liu
Jia Liu
KXKaiDe Xia
KaiDe Xia
Background: To characterize U.S. mortality trends for diabetes mellitus (DM), proxy-defined metabolic dysfunction–associated steatotic liver disease (MASLD), and deaths listing both conditions, and to present exploratory conditional overlap extrapolations through 2040. Methods: We analyzed CDC WONDER multiple-cause-of-death data from 1999–2023 among adults aged ≥25 years. DM was identified by ICD-10 codes E10–E14 and steatotic liver disease by K75.8 or K76.0. Because clinical MASLD cannot be directly ascertained in CDC WONDER, MASLD was defined using a death-certificate proxy combining steatotic liver disease codes with recorded cardiometabolic conditions. Age-adjusted mortality rates were assessed using Joinpoint regression. Prophet models generated conditional extrapolations through 2040. Sensitivity analyses used K76.0-only coding, K75.8-only coding, restriction to 1999–2019, and an underlying-cause-of-death-only analysis requiring K76.0 to be listed as the underlying cause of death. Results: DM-involved mortality changed little from 1999 to 2023 (118.47 to 122.61 per 100,000; average annual percent change [AAPC], −0.03%). In contrast, overlap mortality increased from 0.08 to 0.84 per 100,000 (AAPC, 11.20%), and proxy-defined MASLD mortality increased from 0.13 to 1.29 per 100,000 (AAPC, 9.83%), although absolute rates remained low. Sensitivity analyses using K76.0-only coding, restriction to 1999–2019, and an underlying-cause-of-death-only definition showed directionally consistent increases, whereas K75.8-only overlap deaths were sparse, zero, or suppressed. The underlying-cause-only analysis also showed a directionally consistent increase from 2000 to 2023 (AAPC, 14.46%; 95% CI, 13.46 to 21.51). Conditional extrapolations suggested continued growth through 2040 but were inherently uncertain. Conclusions: Proxy-based mortality involving co-recorded DM and steatotic liver disease increased substantially in U.S. death-certificate data. These findings were directionally consistent across alternative coding, period-restricted, and underlying-cause-only sensitivity analyses but remain limited by under-ascertainment, misclassification, and evolving death-certificate documentation. They should be interpreted as descriptive surveillance patterns rather than evidence of biological expansion or causal mechanisms.